期刊文献+

国产替比培南体外杀菌及耐药性 被引量:2

In vitro bactericidal activity and resistant mutation of domestic tebipenem
原文传递
导出
摘要 目的评价国产替比培南对我国2009—2011年临床分离致病菌的体外杀菌作用及耐药菌产生情况。方法 53株致病菌为2009—2011年北京、济南、上海、广州、深圳、武汉、重庆、长沙和昆明9座城市的9家医院临床分离而得。替比培南的最低杀菌浓度(MBC)测定采用标准肉汤二倍稀释法,替比培南及对照抗菌药的杀菌曲线绘制及耐药研究采用菌落计数法。结果 MBC和杀菌曲线测定表明,替比培南对所测53株菌中50株菌的MBC/最低抑菌浓度(MIC)≤2,且随药物浓度升高,杀菌速率无明显提升,为时间依赖性杀菌药物。耐药频率及诱导耐药试验显示,替比培南药物浓度≥4倍MIC时,自然耐药突变频率基本≤10-8,连续14代诱导的MIC值改变不超过4倍,不易诱导产生耐药。结论国产替比培南对我国2009—2011年临床分离革兰阳性及阴性致病菌均具有很强的杀菌作用,且不易诱导产生耐药,值得进一步研究。 AIM To evaluate the in vitro bactericidal activity and resistant mutation of domestic tebipenem against clinical isolated bacteria in China from 2009 —2011. METHODS A total of 53 strains collected from 9 hospitals in Beijing, Jinan, Shanghai, Guangzhou, Shenzhen, Wuhan, Chongqing,Changsha and Kunming were involved in the study. The minimal bactericidal concentrations( MBC) were determined by the twofold broth dilution method. Time- kills and resistance study were tested by colony form unit(CFU) count method. RESULTS The MBCs and time- kill curves showed that the specific values of MBC/MIC of tebipenem against 50 strains were ≤ 2, and there were no significant change of bactericidal rate with increased drug concentrations. So, tebipenem was a time- depended bactericidal agent. When tebipenem drug concentration ≥ 4 times MIC, the spontaneous mutant frequency ≤ 10-8. The changes of tebipenem MIC values were within 4 times MIC when srtains were sub- cultured to 14 generations in media. So, it is not easy to induce resistance against tebipenem. CONCLUSION Domestic tebipenem shows excellent bactericidal activity againstclinical isolated gram- positive and- negative bacteria in China from 2009—2011 and low induce resistance. It was deserved further study.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2014年第10期719-724,共6页 Chinese Journal of New Drugs and Clinical Remedies
关键词 替比培南 体外研究 杀菌作用 抗药性 tebipenem in vitro bactericidal activity drug resistance
  • 相关文献

参考文献8

  • 1KOBAYASHI R,KONOMI M,HASEGAWA K,et al.In vito activity of tebipenem,a new oral carbapenem antibiotic against penicillin-nonsusceptible Streptococcus pneumoniae[J].Antimicrob Agents Chemother,2005,49(3):889-894.
  • 2FUJISAKI M,SADAMOTO S,IKEDO M,et al.Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp.and Haemophilus influenzae[J].J Infect Chemother,2011,17(1):17-23.
  • 3李耘,薛峰,刘健,杨维维,张佳,吕媛.国产替比培南体外抗菌活性[J].中国新药与临床杂志,2014,33(12):900-906. 被引量:1
  • 4HIKIDA M,ITAHASHI K,IGARASHI A,et al.In vitro antibacterial activity of LJC 11,036,an active metabolite of L-084,a new oral carbapenem antibiotic with potent antipneumococcal activity[J].Antimicrob Agents Chemother,1999,43(8):2010-2016.
  • 5MIYAZAKI S,HOSOYAMA T,FURUYA N,et al.In vitro and in vivo antibacterial activities of L-084,a novel oral carbapenem,against causative organisms of respiratory tract infections[J].Antimicrob Agents Chemother,2001,45(1):203-207.
  • 6KISHII K,CHIBA N,MOROZUMI M,et al.In vitro activity of tebipenem,a new oral carbapenem antibiotic,againstβ-lactamase-nonproducing,ampicillin-resistant Haemophilus influenzae[J].Antimicrob Agents Chemother,2010,54(9):3970-3973.
  • 7ZHAO X,DRLICA K.Restricting the selection of antibioticresistant mutants:a general strategy derived from fluoroquinolones studies[J].Clin Infect Dis,2001,33suppl:S147-S156.
  • 8ZHAO X,DRLICA K.Restricting the selection of antibioticresistant mutants:measurement and potential use of the mutant selection window[J].J Infect Dis,2002,185(64):561-565.

二级参考文献11

  • 1刘成伟,黄文祥,卓超,余登高,李崇智,郑行萍.法罗培南对临床分离194株致病菌的体外抗菌活性研究[J].重庆医科大学学报,2006,31(1):107-109. 被引量:8
  • 2李家泰.临床药理学[M].北京:人民卫生出版社,2007.
  • 3HIKIDA M,ITAHASHI K,IGARASHI A,et al.In vitro antibacterial activity of LJC 11,036,an active metabolite of l-084,a new oral carbapenem antibiotic with potent antipneumococcal activity[J].Antimicrob Agents Chemother,1999,43(8):2010-2016.
  • 4MIYAZAKI S,HOSOYAMA T,FURUYA N,et al.In vitro and in vivo antibacterial activities of L-084,a novel oral carbapenem,against causative organisms of respiratory tract infections[J].Antimicrob Agents Chemother,2001,45(1):203-207.
  • 5FUJISAKI M,SADAMOTO S,IKEDO M,et al.Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp.and Haemophilus influenzae[J].J Infect Chemother,2011,17(1):17-23.
  • 6KISHII K,CHIBA N,MOROZUMI M,et al.In vitro activity of tebipenem,a new oral carbapenem antibiotic,againstβ-lactamase-nonproducing,ampicillin-resistant Haemophilus influenzae[J].Antimicrob Agents Chemother,2010,54(9):3970-3973.
  • 7MURAMATSU H,HORII T,MORITA M,et al.Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates[J].Int J Med Microbiol,2003,293(2-3):191-197.
  • 8GOLDSTEIN EJC,CITRON DM.Activity of a novel carbapenem,doripenem,against anaerobic pathogens[J].Diagn Microbiol Infect Dis,2009,63(4):447-454.
  • 9TANAKA K,MIKAMO H,NAKAO K,et al.In vitro activity of tomopenem(CS-023/RO4908463)against anaerobic bacteria[J].Antimicrob Agents Chemother,2009,53(1):319-322.
  • 10李耘,胡志东,刘文恩,李曼宁,吕媛,薛峰,刘健,郑波,张秀珍,胡云建,赵建宏,潘世扬,赵旺胜,胡必杰,邓秋连,周玲,董方,府伟灵,徐修礼,裴凤艳,孟灵,季萍,杨维维,张佳.我国2009至2010年MOHNARIN项目临床分离常见病原菌的耐药监测[J].中华检验医学杂志,2012,35(1):67-87. 被引量:116

同被引文献14

  • 1刘成伟,黄文祥,卓超,余登高,李崇智,郑行萍.法罗培南对临床分离194株致病菌的体外抗菌活性研究[J].重庆医科大学学报,2006,31(1):107-109. 被引量:8
  • 2李家泰.临床药理学[M].北京:人民卫生出版社,2007.
  • 3KOBAYASHI R,KONOMI M,HASEGAWA K,et al.In vito activity of tebipenem,a new oral carbapenem antibiotic against penicillin-nonsusceptible Streptococcus pneumoniae[J].Antimicrob Agents Chemother,2005,49(3):889-894.
  • 4FUJISAKI M,SADAMOTO S,IKEDO M,et al.Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp.and Haemophilus influenzae[J].J Infect Chemother,2011,17(1):17-23.
  • 5KISHII K,CHIBA N,MOROZUMI M,et al.In vitro activity of tebipenem,a new oral carbapenem antibiotic,againstβ-lactamase-nonproducing,ampicillin-resistant Haemophilus influenzae[J].Antimicrob Agents Chemother,2010,54(9):3970-3973.
  • 6HIKIDA M,ITAHASHI K,IGARASHI A,et al.In vitro antibacterial activity of LJC 11,036,an active metabolite of l-084,a new oral carbapenem antibiotic with potent antipneumococcal activity[J].Antimicrob Agents Chemother,1999,43(8):2010-2016.
  • 7MIYAZAKI S,HOSOYAMA T,FURUYA N,et al.In vitro and in vivo antibacterial activities of L-084,a novel oral carbapenem,against causative organisms of respiratory tract infections[J].Antimicrob Agents Chemother,2001,45(1):203-207.
  • 8FUJISAKI M,SADAMOTO S,IKEDO M,et al.Development of interpretive criteria for tebipenem disk diffusion susceptibility testing with Staphylococcus spp.and Haemophilus influenzae[J].J Infect Chemother,2011,17(1):17-23.
  • 9KISHII K,CHIBA N,MOROZUMI M,et al.In vitro activity of tebipenem,a new oral carbapenem antibiotic,againstβ-lactamase-nonproducing,ampicillin-resistant Haemophilus influenzae[J].Antimicrob Agents Chemother,2010,54(9):3970-3973.
  • 10MURAMATSU H,HORII T,MORITA M,et al.Effect of basic amino acids on susceptibility to carbapenems in clinical Pseudomonas aeruginosa isolates[J].Int J Med Microbiol,2003,293(2-3):191-197.

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部